e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Drug resistance among new TB cases and relapses
P. Victor, R. Larisa, Y. Marina, K. Lev, E. Putova (Moscow, Russian Federation)
Source:
Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Session:
Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Session type:
Thematic Poster Session
Number:
2620
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Victor, R. Larisa, Y. Marina, K. Lev, E. Putova (Moscow, Russian Federation). Drug resistance among new TB cases and relapses. Eur Respir J 2011; 38: Suppl. 55, 2620
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Drug resistance rates in soldier patients newly diagnosed with TB
Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups
Year: 2008
Drug resistant TB treatment outcomes in Novokuznetsk
Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control
Year: 2007
Drug resistance in tuberculosis
Source: Eur Respir J 2005; 25: 376-379
Year: 2005
Drug resistant tuberculosis in hospitalized patients
Source: Eur Respir J 2006; 28: Suppl. 50, 10s
Year: 2006
Drug resistance pattern and outcome of treatment in recurrent episodes of tuberculosis
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Drug resistance pattern of directly observed treatment shortcourse (DOTS) category-II relapse patients
Source: Annual Congress 2011 - Tuberculosis epidemiology and public health
Year: 2011
Antituberculous drug resistance rates in soldier patients newly diagnosed with TB in Turkey
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Monitoring of drug resistance of TB mycobacteria in new pulmonary TB patients
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Antituberculosis drug resistance rates in patients newly diagnosed with TB in Istanbul
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Year: 2012
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre
Source: Eur Respir J 2003; 22: Suppl. 45, 524s
Year: 2003
Drug resistance and tuberculosis elimination in low-incidence countries
Source: Eur Respir J 2014; 44: 1408-1411
Year: 2014
Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Medico-social features of resistance development to new anti–TB drugs in patients with MDR/XDR TB
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Drug resistance in pulmonary TB patients: Analysis of dynamics
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
Drug resistance in previously treated patients of tuberculosis in pre DOTS and DOTS era and its implications
Source: Annual Congress 2009 - Tuberculosis control
Year: 2009
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept